Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB1 | P05556 | 10/20 | 0.66 |
| ▸ | ITGAV | P06756 | 2/20 | 0.66 |
| ▸ | ITGA4 | P13612 | 7/20 | 0.44 |
| ▸ | ITGB7 | P26010 | 5/20 | 0.44 |
| ▸ | TACR3 | P29371 | 1/20 | 0.41 |
| ▸ | CDK2 | P24941 | 5/20 | 0.41 |
| ▸ | ITGA5 | P08648 | 2/20 | 0.39 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.39 |
| ▸ | ITGA2 | P17301 | 1/20 | 0.38 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3317053 | 0.91 | ITGB1 (0.79) | ITGB1ITGAVITGA4ITGB7ITGA5 | |
| SCHEMBL8353596 | 0.90 | ITGB1 (0.80) | ITGB1ITGAVITGA4ITGB7TACR3 | |
| SCHEMBL3319924 | 0.90 | ITGB1 (0.80) | ITGB1ITGAVITGA4ITGB7TACR3 | |
| SCHEMBL3315770 | 0.90 | ITGB1 (0.80) | ITGB1ITGAVITGA4ITGB7TACR3 | |
| SCHEMBL4625311 | 0.88 | ITGB1 (0.70) | ITGB1ITGAVITGA4ITGB7TACR3 | |
| SCHEMBL1028109 | 0.87 | ITGB1 (0.72) | ITGB1ITGAVITGA4ITGB7TACR3 | |
| SCHEMBL3314959 | 0.85 | ITGB1 (0.72) | ITGB1ITGAVITGA4ITGB7TACR3 | |
| SCHEMBL4627302 | 0.83 | ITGB1 (0.69) | ITGB1ITGAVITGA4ITGB7TACR3 | |
| SCHEMBL3313321 | 0.83 | ITGB1 (0.69) | ITGB1ITGAVITGA4ITGB7TACR3 | |
| SCHEMBL3314709 | 0.83 | ITGB1 (0.63) | ITGB1ITGAVITGA4ITGB7TACR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1501801-B1 | 2,6-QUINOLINYL AND 2,6-NAPHTHYL DERIVATIVES AND THEIR USE IN THE TREATMENT OF VLA-4 DEPENDENT DISEASES | UCB PHARMA SA (BE) | 2008-01-23 | — | — | EP | claimed |
| US-20100105681-A1 | 2,6-QUINOLINYL AND 2,6-NAPHTHYL DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES AS VLA-4 INHIBITORS | LASSOIE MARIE-AGNES | 2010-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105681-A1 | 2,6-QUINOLINYL AND 2,6-NAPHTHYL DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES AS VLA-4 INHIBITORS | SCN4A, NECTIN4, VPS4B | ITGB1 274/4885ITGAV 65/4885ITGA4 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.